Details About Generic Salt ::  Toremife

Main Medicine Class::    

(TORE-EM-ih-feen)

Fareston

Oral tablets

60 mg

Class: Antiestrogen hormone

 Indications Metastatic breast cancer in postmenopausal women.

 Contraindications Standard considerations.

 Route/Dosage

Breast Cancer

ADULTS: PO 60 mg once daily with or without food.

Interactions

Anticonvulsants

May increase toremifene clearance by 2-fold.

CYP3A4

Toremifene may be altered by drugs that inhibit (eg, ketoconazole, itraconazole, macrolides) or induce (eg, phenobarbital, phenytoin, carbamazepine) this enzyme.

Thiazide diuretics

May cause hypercalcemia with agents that reduce renal excretion of calcium.

Warfarin

May increase the hypoprothrombinemic effect of warfarin.

Lab Test Interferences None well documented.

 Adverse Reactions

CARDIOVASCULAR: Edema; pulmonary embolism; thrombophlebitis; thrombosis; cerebrovascular accident; transient ischemic attack; cardiac failure; MI. CNS: Dizziness. ENDOCRINE: Hot flashes; sweating. GI: Nausea and vomiting; elevated LFTs. GU: Vaginal discharge; vaginal bleeding; endometrial thickening. METABOLIC: Hypercalcemia. MUSCULOSKELETAL: Bone and tumor pain at initiation of therapy; soft tissue lesions can temporarily increase in size. SPECIALSENSES: Cataracts; dry eyes; abnormal visual fields; corneal keratopathy; glaucoma; abnormal vision; diplopia.

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Hypercalcemia and tumor flare: Drugs that decrease renal calcium excretion (eg, thiazide diuretics) may increase the risk of hypercalcemia in patients receiving toremifene. Hepatic dysfunction: Metabolized in the liver; dose reduction may be necessary in patients with liver disease. Thromboembolic disease: Caution in patients with thromboembolic diseases. Preexisting endometrial hyperplasia: Avoid long-term use.

PATIENT CARE CONSIDERATIONS

 Administration/Storage

• Store at room temperature. Protect from heat and light.
• Administer PO without regards to food.

 Assessment/Interventions

• Tumor flare and hypercalcemia may occur during the first few weeks of treatment. Monitor serum calcium concentrations periodically.
• Monitor CBC and LFTs periodically during therapy.
• Monitor leukocyte and platelet counts.

OVERDOSAGE: SIGNS & SYMPTOMS   Vertigo, headache, dizziness, nausea, vomiting, reversible hallucinations, ataxia

 Patient/Family Education

• Instruct patient to contact the health care provider if vaginal bleeding occurs.
• Inform patient with bone metastases of typical signs/symptoms of hypercalcemia. Contact the health care provider if such signs or symptoms occur.

Medicscientist Drug Facts

Drugs Class ::

Indications for Drugs ::

 Indications Metastatic breast cancer in postmenopausal women.

Drug Dose ::

 Route/Dosage

Breast Cancer

ADULTS: PO 60 mg once daily with or without food.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category D. Lactation: Undetermined. Children: Safety and efficacy not established. Hypercalcemia and tumor flare: Drugs that decrease renal calcium excretion (eg, thiazide diuretics) may increase the risk of hypercalcemia in patients receiving toremifene. Hepatic dysfunction: Metabolized in the liver; dose reduction may be necessary in patients with liver disease. Thromboembolic disease: Caution in patients with thromboembolic diseases. Preexisting endometrial hyperplasia: Avoid long-term use.

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Edema; pulmonary embolism; thrombophlebitis; thrombosis; cerebrovascular accident; transient ischemic attack; cardiac failure; MI. CNS: Dizziness. ENDOCRINE: Hot flashes; sweating. GI: Nausea and vomiting; elevated LFTs. GU: Vaginal discharge; vaginal bleeding; endometrial thickening. METABOLIC: Hypercalcemia. MUSCULOSKELETAL: Bone and tumor pain at initiation of therapy; soft tissue lesions can temporarily increase in size. SPECIALSENSES: Cataracts; dry eyes; abnormal visual fields; corneal keratopathy; glaucoma; abnormal vision; diplopia.

Drug Mode of Action ::  

Drug Interactions ::

Interactions

Anticonvulsants

May increase toremifene clearance by 2-fold.

CYP3A4

Toremifene may be altered by drugs that inhibit (eg, ketoconazole, itraconazole, macrolides) or induce (eg, phenobarbital, phenytoin, carbamazepine) this enzyme.

Thiazide diuretics

May cause hypercalcemia with agents that reduce renal excretion of calcium.

Warfarin

May increase the hypoprothrombinemic effect of warfarin.

Drug Assesment ::

 Assessment/Interventions

• Tumor flare and hypercalcemia may occur during the first few weeks of treatment. Monitor serum calcium concentrations periodically.
• Monitor CBC and LFTs periodically during therapy.
• Monitor leukocyte and platelet counts.

Drug Storage/Management ::

 Administration/Storage

• Store at room temperature. Protect from heat and light.
• Administer PO without regards to food.

Drug Notes ::

 Patient/Family Education

• Instruct patient to contact the health care provider if vaginal bleeding occurs.
• Inform patient with bone metastases of typical signs/symptoms of hypercalcemia. Contact the health care provider if such signs or symptoms occur.

Medicscientist Drug Facts

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.